Literature DB >> 23327293

Impact of substrate protonation and tautomerization states on interactions with the active site of arginase I.

Shanthi Nagagarajan1, Fengtian Xue, Alexander D MacKerell.   

Abstract

Human arginase is a binuclear manganese metalloenzyme that participates in the urea cycle. Arginase catalyzes the hydrolysis of L-arginine into L-ornithine and urea and is linked to several disorders such as asthma and cancer. Currently, the protonation and tautomerization state of the substrate when bound to the active site, which contains two manganese ions, is not known. Knowledge of the charge-dependent behavior of arginine in the arginase I environment would be of utility toward understanding the catalytic mechanism and designing inhibitors of this enzyme. The arginine(+/0) species, including all possible neutral tautomers, were modeled using an aminoimidazole analog as template. All-atom molecular dynamics simulations were then performed on each of the charged and neutral species. In addition, a hydroxide ion was included in selected simulations to test its importance. Results show that the positively charged state of arginine is stable in the active site of arginase I, with that stabilization facilitated by the presence of hydroxide. Glu277 is indicated to play a role in stabilizing arginine in the active site and facilitating its ability to assume a catalytically competent conformation in the presence of hydroxide. The reported interactions and modeled arginine-bound arginase I structures can be used as a tool for structure-based inhibitor design, as experimental data on the structure of the substrate-enzyme complex is lacking.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23327293      PMCID: PMC3590304          DOI: 10.1021/ci300506y

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  34 in total

1.  Structural and functional importance of first-shell metal ligands in the binuclear manganese cluster of arginase I.

Authors:  Evis Cama; Frances A Emig; David E Ash; David W Christianson
Journal:  Biochemistry       Date:  2003-07-01       Impact factor: 3.162

2.  CHARMM-GUI: a web-based graphical user interface for CHARMM.

Authors:  Sunhwan Jo; Taehoon Kim; Vidyashankara G Iyer; Wonpil Im
Journal:  J Comput Chem       Date:  2008-08       Impact factor: 3.376

Review 3.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

4.  Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA.

Authors:  T Gotoh; M Araki; M Mori
Journal:  Biochem Biophys Res Commun       Date:  1997-04-17       Impact factor: 3.575

5.  Is arginine charged in a membrane?

Authors:  Libo Li; Igor Vorobyov; Alexander D MacKerell; Toby W Allen
Journal:  Biophys J       Date:  2007-11-02       Impact factor: 4.033

Review 6.  Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications.

Authors:  Li Zhou; Dong-Ya Zhu
Journal:  Nitric Oxide       Date:  2009-03-17       Impact factor: 4.427

7.  Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Authors:  Paulo C Rodriguez; David G Quiceno; Jovanny Zabaleta; Blair Ortiz; Arnold H Zea; Maria B Piazuelo; Alberto Delgado; Pelayo Correa; Jason Brayer; Eduardo M Sotomayor; Scott Antonia; Juan B Ochoa; Augusto C Ochoa
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

Review 8.  The human arginases and arginase deficiency.

Authors:  R Iyer; C P Jenkinson; J G Vockley; R M Kern; W W Grody; S Cederbaum
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields.

Authors:  K Vanommeslaeghe; E Hatcher; C Acharya; S Kundu; S Zhong; J Shim; E Darian; O Guvench; P Lopes; I Vorobyov; A D Mackerell
Journal:  J Comput Chem       Date:  2010-03       Impact factor: 3.376

Review 10.  Arginine and immunity: a unique perspective.

Authors:  Carmelo Nieves; Bobbi Langkamp-Henken
Journal:  Biomed Pharmacother       Date:  2002-12       Impact factor: 6.529

View more
  4 in total

Review 1.  Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective.

Authors:  Gonçalo S Clemente; Aren van Waarde; Inês F Antunes; Alexander Dömling; Philip H Elsinga
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

2.  Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2.

Authors:  Trishna Saha Detroja; Abraham O Samson
Journal:  Molecules       Date:  2022-08-12       Impact factor: 4.927

3.  QM/MM Simulations for the Broken-Symmetry Catalytic Reaction Mechanism of Human Arginase I.

Authors:  Sathish Kumar Mudedla; Boyli Ghosh; Gaurao V Dhoke; SeKyu Oh; Sangwook Wu
Journal:  ACS Omega       Date:  2022-08-30

4.  Mapping the Molecular Architecture Required for Lipid-Binding Pockets Using a Subset of Established and Orphan G-Protein Coupled Receptors.

Authors:  Shanthi Nagarajan; Zu Yuan Qian; Parthiban Marimuthu; Nabil J Alkayed; Sanjiv Kaul; Anthony P Barnes
Journal:  J Chem Inf Model       Date:  2021-07-09       Impact factor: 6.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.